ACS - Acute Coronary Syndrome
Conditions
Keywords
Quality indicators, ACS, STEMI, NSTEMI, ESC, Guidelines
Brief summary
Major advances in cardiovascular medicine have been driven by innovations in basic research in biological and technical sciences. Despite the clear evidence regarding the treatments that have been demonstrated to be useful to improve patients' outcomes, their transferability to everyday clinical practice seems to be at least suboptimal. The European Society of Cardiology (ESC), therefore, planned to support a program, denominated EuroHeart, for continuous data collection of standardized and/or harmonized variables in common cardiovascular diseases, such as ACS, HF and A Fib. EuroHeart is an observational, prospective, multicentre initiative with continuous data collection in consecutive patients with ACS, HF and A Fib to support continuous quality of care improvement through the evaluation of quality indicators (QIs) defined by the ESC. All patients included in the EuroHeart initiative, will enter a 12 month longitudinal follow-up with the collection of clinical events and clinical status data.
Interventions
OTHERAdherence to European Society of Cardiology (ESC) quality indicators
EuroHeart is an initiative of the European Society of Cardiology (ESC) supporting continuous quality-of-care improvement through individual patient data collection. The present registry component refers specifically to the Italian implementation of the EuroHeart programme, aimed at monitoring and improving adherence to ESC quality indicators within Italian clinical practice.
Sponsors
Heart Care Foundation
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients ≥18 years of age. * Males and females at birth. * At least one of the following clinical conditions: * Hospitalization for Acute Coronary Syndrome (ACS) * Heart failure (HF, outpatients, and/or inpatients) * Atrial fibrillation (A Fib, outpatients and/or inpatients) * Signed informed consent for the study and for privacy.
Exclusion criteria
* patients who do not sign the consent to participate in the project and/or Privacy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adherence to ESC Quality indicators (Beta blockers prescription at discharge in patients with LVEF ≤40%) | From enrollment to 12 months follow-up | Proportion of patients with LVEF ≤40% who are discharged from hospital on beta blockers. |
| Adherence to ESC Quality indicators (STEMI patients reperfused) | From enrollment to 12 months follow-up | Proportion of patients with STEMI reperfused among those eligible (onset of symptoms to diagnosis \<12 hours) |
| Adherence to ESC Quality indicators (STEMI patients reperfused <90 min) | From enrollment to 12 months follow-up | Proportion of patients with STEMI who receive timely reperfusion with PCI (wire crossing) within 90 minutes from initial diagnostic ECG |
| Adherence to ESC Quality indicators (coronary angiography in NSTEMI patients within 24 hours) | From enrollment to 12 months follow-up | Rate of NSTEMI patients who receive invasive within 24 hours from their diagnosis |
| Adherence to ESC Quality indicators (radial access) | From enrollment to 12 months follow-up | Use of radial access in case of invasive strategy for patients with STEMI and NSTEMI |
| Adherence to ESC Quality indicators (time to reperfusion in STEMI patients) | From enrollment to 12 months follow-up | The time between the initial STEMI diagnosis and arterial access (absolute value) for primary PCI |
| Adherence to ESC Quality indicators (pre-discharge LVEF evaluation in STEMI and NSTEMI patients) | From enrollment to 12 months follow-up | The proportion of patients with STEMI and NSTEMI who have an assessment of their left ventricular ejection fraction (LVEF) before hospital discharge |
| Adherence to ESC Quality indicators (in hospital LDL-c evaluation in STEMI and NSTEMI patients) | From enrollment to 12 months follow-up | The proportion of patients with STEMI and NSTEMI who have their LDL cholesterol measured during hospitalization |
| Adherence to ESC Quality indicators (DAPT prescription at discharge in STEMI and NSTEMI patients) | From enrollment to 12 months follow-up | Proportion of patients with STEMI and NSTEMI discharged on dual antiplatelet therapy |
| Adherence to ESC Quality indicators (LLA prescription at discharge in STEMI and NSTEMI patients) | From enrollment to 12 months follow-up | Proportion of patients discharged from hospital on Lipid Lowering Agents (LLA) |
| Adherence to ESC Quality indicators (ACEi/ARB/ARNI prescription at discharge in patients with LVEF ≤40%) | From enrollment to 12 months follow-up | Proportion of patients with LVEF ≤40% who are discharged from hospital on angiotensin converting enzymes inhibitors (ACEi) or angiotensin receptor blockers (ARBs) or angiotensin receptor-neprilysin inhibitor (ARNI) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiovascular and non-cardiovascular events during follow-up | 12 months follow-up | Proportion of patients with clinical events at 12 months |
Countries
Italy
Contacts
Primary ContactFurio Colivicchi, MD
Backup ContactAldo P Maggioni, MD
Outcome results
None listed